BRIEF-Aralez resubmits NDA for Yosprala to FDA
March 15 (Reuters) - Aralez Pharmaceuticals Inc
* Aralez resubmits to FDA New Drug Application for Yosprala
* FDA is expected to issue Aralez an acknowledgment letter within 30 days of resubmission
* If accepted, acknowledgement would also include a new Prescription Drug User Fee Act date Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.